Midatech Pharma Share Discussion Threads

[aim_trader] 01/10/2018 11:29

Midatech Pharma will be presenting to investors on the evening of Thursday 4th October in London at the Proactive One2One Forum from 6pm. For details click here:

[gwatson56] 28/9/2018 10:55

I agree re misleading. Seems to me that once the mist clears on MTD201 with the regulators and a path to market is known then there may be interest in the co... Disappointed with this share....

[jamtomorrow2] 28/9/2018 02:15

What a complete mess. The non bioequivalence of MTD201 means that the route to approval increases by a couple of years. This means that Midatech US has to be sold in a fire sale which means that the $7m loan needs to be repaid out of the proceeds. The previous comments about Midatech US being close to break even were clearly misleading.

[bandflex] 27/9/2018 11:57

"Upon completion of the Sale, Midatech is required to repay its outstanding loan to MidCap Financial of $7.0 million plus early repayment fees and deferred interest. The remaining proceeds of the Sale (i.e. after Midcap repayment and other transaction costs) are expected to be approximately $4.5 million...."

They will end up with an initial sum of just $4.5m.

[luffness] 27/9/2018 08:58

good to see the results and sale of US business being greeted with a burst of activity here - lol

[jamtomorrow2] 14/9/2018 19:46

6 figure upfront for a product which is supposedly better than SLAR selling $1.6b pa! If that was the best they could do then they should be fired.

[best1467] 13/9/2018 07:59

They will be looking to out licence p3 trial ,I would imagine they will be in discussion now it’s just a case of getting the right deal 6 figure upfront payment and double digit royalties

[jamtomorrow2] 11/9/2018 09:39

But it’s not bioequivalent so as it could potentially now become a blockbuster the FDA are going to require a large Phase 3 on real patients. If it was bioequivalent they could have got away with a small trial on healthy volunteers. Big difference in cost and time.

[nobbygnome] 11/9/2018 07:17

Even biosimilars have to do a small efficacy phase III study and they are essentially exactly the same drug (with a few minor structural differences). So no way Midatech could get away without some efficacy data.

[jamtomorrow2] 10/9/2018 22:36

What did they say “Midatech̵7;s drug is better than Sandostatin LAR, and that drug’s sales are $1.6b pa, yet Midatech’s market cap is mysteriously only £16m”?

I guess all will be revealed in Q1 2019 after the outcome of Midatech’s discussions with the FDA are revealed. What Phase 3 trial will the FDA demand? Midatech are hoping for some quick cheap trial versus SLAR in healthy volunteers. The FDA aren’t likely to agree to Midatech taking over a $1.6b market without a large scale trial on sick patients - I mean let’s get real here. In the unlikely event of some sort of victory against the FDA I’m sure Novartis would file a Citizens Petition for non compatibility. This could all take years to sort out. In the meantime Midatech has no money.

So in a nutshell that’s why a company that could be worth $1b right now is valued at £16m. On the other hand Midatech does look a sitting duck to be taken over by Novartis for $200m thus allowing the original investors to bail out at breakeven. Interesting eh!

[cerrito] 10/9/2018 17:44

Heard about this for the first time today as it was featured in the London Evening Standard

[value viper] 07/9/2018 14:56

buying continues apace ; stock stuck

[value viper] 07/9/2018 10:10

my money is on a placing here - qu. is , at what price and raising how much as always
big spike on recent news (brought lots of buying of course)
many must be nursing losses
more half decent nibbling today and still wont budge
OR seller in background of course (imv unlikely)
something bubbling
BUT actually they said recently they would assess NON DILUTIVE financing options (may be I'm wrong)

[jamtomorrow2] 06/9/2018 10:33

I wonder whether the recent financing was dependent upon MTD201 being bioequivalent to SLAR. As it isn’t that would necessitate a further dilutionary fund raising at a very low price. This may explain the fall back in the price if MTPH is doing the financing rounds right now.

[costax1654x] 03/9/2018 07:48

Sbtx RNS boom time.Big rerate to come

[zen12] 02/9/2018 14:04

Also, potential partners should be queuing up here. A 1.5bn/yr market with a product that is proving significantly better than what’s in the market today. FDA Approvals are part and parcel of pharma’a and allies to wonder drugs alike, so wouldn’t see this is a red-herring. The key is drug & additionally the new Tech.

[zen12] 02/9/2018 13:45

Similar companies also have these complications uswell so is nothing new. Think with drug being significantly superior and new Tech could be massive money spinner, interesting days and weeks ahead.

[nobbygnome] 01/9/2018 09:24

Jam tomorrow is technically correct; it will make the phase III more complicated. However, overall the drug formulation is more valuable because it is superior. So swings and roundabouts really......

IMHO the technology platform is now a great valuable asset.

Nobby

[riddlerone] 01/9/2018 09:23

Finished near session highs

[riddlerone] 01/9/2018 09:20

"Following close behind was fellow pharma firm Midatech, shares in which rose 33.6 per cent to 34.7p after new data released today for its MTD201 drug suggested it could be better than a rival product made by Swiss firm Novartis, one of the world’s biggest pharmaceutical companies.

MTD201 is being developed as a treatment for a hormonal disorder called acromegaly as well as for carcinoid cancer.

Novartis has already cornered a large slice of the market with its Sandostatin LAR drug, but the interim data has shown MTD201 to be, at worst, a good alternative or, at best, a 'differentiated improved product"

[best1467] 01/9/2018 08:51

Not sure how you can view it as a negative with a superior product a partner should be found with milestone and royalties down the line which even in the short term should give a substantial lift to the current valuation.

[jamtomorrow2] 01/9/2018 04:55

You said it. It’s not bioequivalent - but it is potentially better. The problem is that you will have to prove that to the FDA in a large Phase 3 trial. That’s going to cost time and big money, which Midatech doesn’t have. It will therefore need to partner the product and take upfronts and royalties as opposed to keeping 100% control of the product and selling it through Dara. The mathematics of all this are far from straightforward hence the modest share price reaction.

[zen12] 31/8/2018 23:09

But they forgot the other big development tech Q-Sphera!
‘ Second, this study is a major validation and inflection point for Midatech's Q-Sphera™ technology establishing it as an exciting new sustained-release delivery platform, to administer pharmaceuticals safely, conveniently and effectively, without a burst phenomenon, and over a prolonged period. After five years of development, we are delighted to have achieved positive first-in-human data. We look forward to unlocking the full potential of our MTD201 programme as well as the Q-Sphera platform, both for Midatech and for our partners looking to capture a share of the multibillion dollar sustained-release treatment opportunities.’;

[zico01] 31/8/2018 22:54

Nice write-up in Daily Mail:

Stock Watch - Midatech Pharma

A cure for cancer may have come a step closer for Midatech Pharma.

The small drugs company today announced positive results from its latest trial of MTD201, used to cure carcinoid cancer, which affects the hormone system, and acromegaly, where the body produces too much growth hormone.

The trial suggested the product was better than any on sale. The market for this type of treatment is worth around £1.5billion per year. Shares jumped 19.2 per cent, or 5p, to 31p.